BMYMirati Therapeutics Inc.Running, no new patients
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Advanced Colorectal Cancer · Metastatic Colorectal Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 461 (final count)
- Started
- Jun 24, 2021
- Main results expected
- Jan 16, 2026
- Fully finished
- Oct 23, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: 30 months
Progression-free Survival (PFS)
Measured over: 30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04793958 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC